RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

Benzinga Newsdesk www.benzinga.com Negative 91.5%

Neg 91.5% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $299 to $296.